
General
FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
May 27, 2016
|
The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected
Read More